Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
202
Recruiting, any sponsor type, condition "chronic kidney disease"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting202
- Completed1,593
202 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT03969329 · 24 participants (planned) · Start Dec 20, 2019 · Primary completion Jun 30, 2027
Drug: Etelcalcetide · For: Secondary Hyperparathyroidism
Sites: Ghent, Belgium; Prague, Czechia; Bron, France · 23 sites in all
Singulera Therapeutics Inc.Industry
NCT06552169 · 34 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 2027
Drug: Arm 1: SOC (mTOR + CNI); Arm 2A: TRACT/MONO mTOR and 1 more · For: Kidney Transplantation
Sites: Phoenix, Arizona; Chicago, Illinois; Rochester, Minnesota · 7 sites in all
VA Office of Research and DevelopmentFederal agency
NCT06013865 · 264 participants (planned) · Start Apr 5, 2024 · Primary completion Mar 31, 2030
Drug: Empagliflozin · For: Kidney Transplant; Chronic Kidney Disease
Sites: Hines, Illinois; Iowa City, Iowa; Omaha, Nebraska · 5 sites in all
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Pivotal-lookingRecruiting
Kind Pharmaceuticals LLCIndustry
NCT07487727 · 240 participants (planned) · Start Dec 3, 2025 · Primary completion Mar 1, 2027
Drug: AND017; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Beijing, China
- Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and SurvivalPivotal-lookingRecruiting
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT06431919 · 260 participants (planned) · Start Jun 10, 2025 · Primary completion Jan 31, 2028
Drug: Simvastatin 20mg; Carvedilol 3.125 mg · For: Decompensated Cirrhosis; Cirrhotic Cardiomyopathy; Cirrhosis, Liver and 2 more
Sites: Chandigarh, India
- Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft DysfunctionPivotal-lookingRecruiting
Nantes University HospitalAcademic, hospital or other
NCT05562869 · 30 participants (planned) · Start May 3, 2024 · Primary completion Nov 3, 2028
Drug: Belatacept 250 Milligram Intravenous Powder for Solution · For: Chronic Kidney Failure
Sites: Nantes, France
AstraZenecaAstraZeneca (AZN)
NCT07024823 · 192 participants (planned) · Start Jun 9, 2025 · Primary completion Jan 29, 2027
Drug: AZD4248; Placebo and 4 more · For: Chronic Kidney Disease
Sites: Glendale, California; Chicago, Illinois; Ann Arbor, Michigan · 5 sites in all
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07235059 · 112 participants (planned) · Start Nov 20, 2025 · Primary completion Jan 21, 2028
Drug: OJR520 · For: Chronic Kidney Disease
Sites: Miami, Florida; Berlin, Germany
Hansa Biopharma ABIndustry
NCT05753930 · 10 participants (planned) · Start Jun 2, 2023 · Primary completion Feb 28, 2027
Drug: Imlifidase · For: Kidney Transplantation in Highly Sensitized Patients
Sites: Helsinki, Finland; Paris, France; Rome, Italy · 7 sites in all
- Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal DiseaseRecruiting
Xeno Holdings (US), LLC dba ChoironeXIndustry
NCT07696962 · 4 participants (planned) · Start Nov 2026 · Primary completion Jun 30, 2028
Drug: ChoironeX GalKO Porcine Thymokidney · For: End Stage Renal Disease
Sites: New York, New York · 2 sites in all
- Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
University of ArkansasAcademic, hospital or other
NCT07911124 · 230 participants (planned) · Start Nov 2026 · Primary completion Dec 2030
Drug: Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist; Placebo · For: Chronic Kidney Disease (CKD)
Sites: Little Rock, Arkansas
Akebia TherapeuticsIndustry
NCT07268638 · 60 participants (planned) · Start Dec 3, 2025 · Primary completion Jun 2027
Drug: Praliciguat (Part A); Praliciguat (Part B) · For: Focal Segmental Glomerulosclerosis
Sites: Chula Vista, California; Garden Grove, California; Los Angeles, California · 32 sites in all
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
NCT07391267 · 90 participants (planned) · Start May 25, 2026 · Primary completion Dec 31, 2028
Drug: Semaglutide Oral Tablet · For: Chronic Kidney Diseases; MAFLD
Sites: New Delhi, India
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07498335 · 28 participants (planned) · Start Aug 6, 2026 · Primary completion Sep 15, 2031
Drug: Drug: Atrasentan · For: Berger Disease; Bergers Disease; IgA Nephropathy and 3 more
Sites: Neptune City, New Jersey; Cincinnati, Ohio; Oklahoma City, Oklahoma · 23 sites in all
BayerBayer (BAYRY)
NCT06278207 · 50,000 participants (planned) · Start May 15, 2024 · Primary completion Sep 30, 2027
Drug: Finerenone (BAY 94-8862) · For: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Sites: Many Locations, New Jersey; Berlin, Germany; Many Locations, Japan · 4 sites in all
Instituto de Investigación Biomédica de SalamancaAcademic, hospital or other
NCT07348484 · 300 participants (planned) · Start Apr 1, 2026 · Primary completion Apr 2028
Drug: Empagliflozin · For: Chronic Kidney Disease
Sites: Salamanca, Spain
- Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismPivotal-lookingRecruiting
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07122401 · 424 participants (planned) · Start Sep 30, 2025 · Primary completion Nov 26, 2026
Drug: MT1013; Cinacalcet · For: Secondary Hyperparathyroidism, Chronic Kidney Disease
Sites: Shanghai, China
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07241390 · 7,140 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 2031
Drug: Orforglipron; Placebo · For: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina · 566 sites in all
- UBT251 Injection Phase II Clinical Study (CKD)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07134335 · 180 participants (planned) · Start Sep 1, 2025 · Primary completion Jul 11, 2030
Drug: UBT251; UBT251 and 1 more · For: Obesity &Amp; Overweight; Chronic Kidney Disease
Sites: Beijing, China
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07783802 · 120 participants (planned) · Start Aug 27, 2026 · Primary completion May 2027
Drug: Clazakizumab; Placebo · For: Atherosclerosis; Cardiovascular Disease; Obesity and 3 more
Sites: Huntsville, Alabama; Tucson, Arizona; Glendora, California · 46 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06434363 · 47 participants (planned) · Start Jul 31, 2024 · Primary completion Dec 31, 2028
Drug: Tafasitamab; Fludarabine phosphate and 2 more · For: Autoimmune Disorders; Systemic Sclerosis; Systemic Lupus Erythematosus and 2 more
Sites: Houston, Texas · 2 sites in all
Chittagong Medical CollegeAcademic, hospital or other
NCT07912359 · 96 participants (planned) · Start Oct 11, 2026 · Primary completion Nov 11, 2027
Drug: Experimental arm will get synbiotic therapy containing Lactobacillus acidophilus (15 billion CFU), Bifidobacterium longum (15 billion CFU), Streptococcus thermophilus(15 billion CFU), along with xylo · For: Chronic Kidney Disease (Stage 3-4)
Sites: Chittagong, Bangladesh
Atom Therapeutics Co., LtdIndustry
NCT07323095 · 80 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 31, 2027
Drug: ABP-671 plus febuxostat Group 1; ABP-671 plus febuxostat Group 2 and 2 more · For: Chronic Kidney Disease
Sites: Gosford, Australia; Newcastle, Australia; Brisbane, Australia · 10 sites in all
- Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKDPivotal-lookingRecruiting
Emory UniversityAcademic, hospital or other
NCT05928936 · 156 participants (planned) · Start Nov 11, 2022 · Primary completion Jun 1, 2028
Drug: Sodium Bicarbonate; Placebo · For: Chronic Kidney Disease
Sites: Atlanta, Georgia; Decatur, Georgia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.